Bottom Line on the Three New Drugs

A note from TheBody.com: The field of medicine is constantly evolving. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Enfuvirtide (T-20, Fuzeon)

Enfuvirtide is an injectable anti-HIV drug approved by the FDA for people with multi-drug resistance to other anti-HIV therapies.

It appears safe, with the primary side effect of injection site reactions.

Enfuvirtide appears to be active and useful for people who have failed other therapies and represents a hopeful new option for people.

Advertisement

Being an injectable therapy, it may be difficult to use and requires training for doctors and patients alike to administer the drug to maximize benefits and minimize side effects.

Atazanavir (Reyataz)

The new protease inhibitor is designed for once daily dosing; its ease of use provides an intriguing option for part of a first line regimen. When boosted with a small amount of ritonavir it may provide an additional tool in the arsenal for third line therapy.

There are many potential drug interactions with atazanavir, and people are encouraged to pay particular attention to these when adding this drug to their regimen.

Emtricitabine (FTC, Emtriva)

This NRTI appears similar to 3TC (lamivudine, Epivir), but requires only once-daily dosing and resistance may be less likely to develop to FTC.

A note from TheBody.com: The field of medicine is constantly evolving. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

This article was provided by Project Inform. It is a part of the publication Project Inform Perspective. Visit Project Inform's website to find out more about their activities, publications and services.

The Body is a service of Remedy Health Media, LLC, 750 3rd Avenue, 6th Floor, New York, NY 10017. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.